International Research Workshop

2023 DTRF International Desmoid Tumor Research Workshop

Friday, September 22, 2023

The DTRF International Desmoid Tumor Research Workshop is part of the DTRF Together We Will Weekend, taking place in Philadelphia, PA. Register for the Weekend here.

Designed for researchers and medical professionals, this critically important, collaborative workshop is a meeting of some of the brightest minds in desmoid tumor research from a variety of disciplines. The Research Workshop not only facilitates new collaborations in research, but also helps DTRF identify research priorities for the coming years. We are sincerely grateful to our attendees who play a key role in advancing the field of desmoid tumor research.

The DTRF International Research Workshop features:
* A forum to share research findings, develop new collaborations, bring new scientists into the research field, and discuss innovations that will lead to new treatments
* Live questions/answers and discussions related to the scientific talks
* Group discussions focusing on gaps in desmoid tumor science and how best to address them through high impact collaborative research
* Posters and pre-recorded scientific talks on current research that attendees are encouraged to view in advance of the meeting

2023 Distinguished Presenters

Jeanne Whiting

Jeanne Whiting

President and Co-Founder, Desmoid Tumor Research Foundation

Introduction

Ben Alman, MD

Ben Alman, MD

Department Chair, Orthopedic Surgery, Duke University

Welcome

Jonathan Noujaim, MD

Jonathan Noujaim, MD

Assistant Clinical Professor of Medicine, Universite de Montreal (Canada)

Tyrosine Kinase Inhibitors in Desmoid type Fibromatosis – a Canadian Multicenter Retrospective CanSaRCC Study

Bernd Kasper, MD, PhD

Bernd Kasper, MD, PhD

Professor, University of Heidelberg, Mannheim University Medical Center, Mannheim Cancer Center, Sarcoma Unit (Germany)

Global Consensus Paper on Desmoid Tumor Management

Gerlinde Wernig, MD

Assistant Professor, Department of Pathology, Stanford University School of Medicine

Studying CD47 blockade as an immunotherapy for desmoid-type fibromatosis.

Kris Vleminckx, PhD

Kris Vleminckx, PhD

Full Professor, Department of Biomedical Molecular Biology, Ghent University (Belgium)

Investigating EZH2 as a druggable mediator of immune cell exclusion in desmoid tumors

Jesse Boehm, PhD

Principal Investigator, Koch Institute, MIT

Progress Towards Creating a Prototype Desmoid Tumor Dependency Map

Cristabelle De Souza, PhD

Cristabelle De Souza, PhD

Postdoctoral Fellow, Cancer Biology, Stanford University

Activation of c-JUN modulates the transcriptional activity of CD63 serving as a novel target for the treatment of desmoid type fibromatosis

Gabe Augdahl

Gabe Augdahl

Desmoid Tumor Patient

Paul Huang, PhD

Head, Molecular and Systems Oncology Laboratory, Division of Molecular Pathology, Institute of Cancer Research (UK)

What has proteomics taught us about desmoid tumours?

Linda Holtzman, MHA, RHIA, CCS, CCS-P, CPC, COC

President, Clarity Coding

New Desmoid Tumor ICD-10-CM Codes

Joanna Przybyl, PhD

Assistant Professor, McGill University (Canada)

Expression of the hexosamine biosynthesis pathway components in desmoid tumors

ABSTRACT

Yoshihiro Nishida, MD

Yoshihiro Nishida, MD

Department of Rehabilitation Medicine and Orthopaedic Surgery, Nagoya University Hospital (Japan)

Treatment for upper limb desmoid causing pain and joint contracture: the importance of medication and rehabilitation

ABSTRACT

Joseph Pressey, MD

Joseph Pressey, MD

Professor of Pediatrics, University of Cincinnati College of Medicine and Cincinnati Children’s Hospital Medical Center

Percutaneous Cryoablation with and without VEGF-Tyrosine Kinase Inhibitor Therapy for Pediatric and Adult Patients with Desmoid Tumors

ABSTRACT

Aaron Weiss, DO

Aaron Weiss, DO

Associate Professor, Department of Pediatrics,  Division Chief, Pediatric Hematology-Oncology, Maine Medical Center

A Pilot Study Evaluating the Use of Sirolimus in Children and Young Adults with Desmoid-type Fibromatosis

ABSTRACT

Jacob Bickels, MD

Jacob Bickels, MD

Orthopedic Oncologist, Hillel-Yaffe Medical Center (Israel)

Microbiome of desmoid tumor and its impact on the clinical course of disease

ABSTRACT 

Ravin Ratan, MD

Associate Professor, Sarcoma Medical Oncology, MD Anderson Cancer Center

Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT):  Results from the phase 3 DeFi study

ABSTRACT

Theirry Alcindor, MD, MSc, FRCPC

Senior Physician, Dana-Farber Cancer Institute and Harvard Medical School

Tumor volume and T2 hyperintensity changes from DeFi: a phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors

ABSTRACT

Rashmi Chugh, MD

Rashmi Chugh, MD

Professor, Division of Hematology/Oncology, University of Michigan Rogel Comprehensive Cancer Center

RINGSIDE Phase 2/3 Trial of AL102 for Treatment of Desmoid Tumors (DT): Phase 2 Results Tumors

ABSTRACT

Recorded Presentations

Jacob Bickels, MD, Orthropedic Oncologist, Hillel-Yaffe Medical Center, Photodynamic Therapy with 5-ALA in the Management of Desmoid Tumors

 

Past Workshops